ABEVMY 400 INJECTION

ABEVMY 400 INJECTION is a recombinant monoclonal antibody that belongs to the immunotherapy class of cancer treatment. It can either be used as monotherapy or in combination with chemotherapy or immunotherapy medications to improve the overall survival rate.

While for women with reproductive potential subjected to ABEVMY 400 INJECTION, it is advised to discuss with your doctor regarding the effective birth control methods during the treatment. Also to be continued for a minimum of 6 months after the treatment course completion as this medicine may impair fertility.

ABEVMY 400 INJECTION is associated with increased risk of bleeding complications and poor wound healing. Hence it is suggested to avoid planning for surgery and maintain an interval of 28days before or after surgery.

All the side effects that are relatively caused by ABEVMY 400 INJECTION occur until the drug concentration stays in the body. It is found that this medicine will be contained in our body for almost 4 months after the final dose.

ABEVMY 400 INJECTION is given intravenously through infusion and the amount of drug will be measured based on the patient’s body weight, height and age. The first dose will be administered for 90 minutes and if well tolerated the infusion time can be reduced to 30 minutes.

Inform your physician before starting your treatment with ABEVMY 400 INJECTION in case, if you are pregnant or planning for pregnancy as this medicine may cause harm to the unborn baby and interrupt the formation of blood vessels.

It is important to inform your physician about all prescription and non-prescription medications, vitamins, and herbal products you are taking before starting treatment with ABEVMY 400 INJECTION. Your doctor will assess potential interactions.

It is important to inform your physician if you have conditions involving inflammation in the stomach (like ulcer or colitis), have experienced allergic reactions to ABEVMY 400 INJECTION or its ingredients, have recently undergone surgery (due to bleeding risk), or have diabetes, hypertension, or heart problems.

The active ingredient in ABEVMY 400 INJECTION is Bevacizumab. Bevacizumab is a monoclonal antibody that targets a protein called VEGF.

ABEVMY 400 INJECTION is used in the treatment of various types of cancers.

ABEVMY 400 INJECTION is an anti-cancer medication that works by preventing the growth of new blood vessels that tumors need to grow and spread.